Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium w (Mw) in BCG [Bacille Calmette-Guerin] Refractory Superficial Transitional Cell Carcinoma.

Trial Profile

Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium w (Mw) in BCG [Bacille Calmette-Guerin] Refractory Superficial Transitional Cell Carcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Cadi 05 (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cadila Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Actual end date Jul 2011 added as reported by ClinicalTrials.gov.
    • 15 Feb 2012 Planned number of patients changed from 20 to 22 as reported by Clinical Trials Registry - India.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top